U.S. Markets closed

Three Companies Using AI and Innovation to Lead Healthcare Sector

HOUSTON, TX / ACCESSWIRE / January 24, 2019 / Healthcare is quickly being disrupted by artificial intelligence.

In fact, AI is quickly proving it can spot warning signs of disease before we're even aware of it ourselves.

"A recent study by researchers at Google showed that AI algorithms could also be used to predict if someone might suffer a heart attack by looking into their eyes," reports the BBC. "Artificial intelligence could also use the way we look to help us predict future disease. New research suggests it can pick up on subtle differences in our faces that might be the hallmarks of disease."

With it, even genetic disorders and debilitating ailments, such as Parkinson's disease, heart issues, depression, and dementia could be a thing of the past.

As the excitement builds, the global healthcare AI market is expected to reach $6.16 billion by 2022, notes Healthcare Informatics. By 2026, experts estimate that AI applications could save the U.S. healthcare economy up to $150 billion, and help address 20% of unmet clinical demand. It could very well improve overall quality of patient care, prevent unnecessary medical costs and procedures while improving on diagnoses and treatment options.

In short, innovation such as AI is leading healthcare.

Some of the most innovative stocks to watch, include AI-company, Cognetivity Neurosciences Ltd. (CSE: CGN)(OTCQB: CGNSF), Blueprint Medicines Corporation (NASDAQ: BPMC), and Sage Therapeutics, Inc. (NASDAQ: SAGE).

Cognetivity Neurosciences Ltd. (CGN)(CGNSF)for example just signed a commercial agreement with Dementias Platform UK (DPUK) to become its ninth industry partner.

Other partners include biopharmaceutical companies AstraZeneca, GlaxoSmithKline and Janssen and ten leading academic institutions which include Cambridge University, Oxford University, Imperial College London and University College London.

Cognetivity's proprietary Integrated Cognitive Assessment (ICA) testing platform will be one of the select cognitive testing tools that are made available by DPUK to studies involving its cohorts – over 2 million individuals from over 50 long-term studies of health.

The ICA is unique in its ability to provide precise, sensitive measurements of subjects' ability to process visual information, and is importantly unaffected by subjects' culture, language and shows no learning effect, allowing it to be continuously used to chart cognition, either at a subject's home or in the clinic. The ICA allows detailed measurement of cognitive performance by testing different areas of the brain to standard cognitive tests, allowing measurement of small changes in cognition in the important but poorly understood pre-symptom phase of dementia.

For More Information on Cognetivity Neurosciences Ltd., Click Here.

Just as innovative, Blueprint Medicines Corporation(BPMC) has seen its shares jump from $45 to more than $70 on excitement that it could be an acquisition target following Eli Lilly's deal to buy Loxo Oncology for $8 billion.

The company has a number of products currently in development to treat specific types of cancer, including non-small cell lung cancer (NSCLC), advanced hepatocellular carcinoma (liver cancer), and fibrodysplasia ossificans progressive. Company management also announced that it has set a goal of having two of its products on the market by the end of 2020, as well.

For More Information on Blueprint Medicines Corporation, Click Here.

Sage Therapeutics, Inc.(NASDAQ:SAGE) has also seen its shares move aggressively higher, jumping from $84 a share to more than $130. All after its experimental drug, SAGE-217 met the primary and secondary endpoints in a Phase 3 clinical study to treat postpartum depression. According to the U.S. FDA, data from the Phase 3 study could be used to support an application for regulatory approval.

In addition, the company is currently evaluating SAGE-217 in Phase 3 clinical studies for the treatment of major depressive disorder, as well. Hopes are running high that SAGE-217 will have similar success to that of postpartum depression results.

For More Information on Sage Therapeutics Inc., Click Here.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media which has a partnership with www.wallstreetnation.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.

For making specific investment decisions, readers should seek their own advice. Winning Media, which has a partnership with www.wallstreetnation.com, is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement between Winning Media (partners of wallstreetnation.com) and Cognetivity Neurosciences Ltd., Winning Media has been paid seventy-five thousand dollars for advertising and marketing services for Cognetivity Neurosciences Ltd. We own ZERO shares of Cognetivity Neurosciences Ltd. Please click herefor full disclaimer.

Contact Information:


SOURCE: wallstreetnation.com